Medizinische Klinik und Poliklinik III, Center for Integrated Oncology (CIO), University of Bonn, Bonn, Germany.
Leuk Res. 2011 Sep;35(9):1136-42. doi: 10.1016/j.leukres.2011.05.005. Epub 2011 Jun 8.
The immune system can be harnessed to fight cancer by active (stimulating the patient's intrinsic immune response to cancer) and by passive (transfer of active humoral or cellular immunity) immunotherapy. While for each strategy proof-of-principle was provided, clinical benefit was limited likely due to malfunction of lymphocytes. Increasing knowledge of both the mechanism of vaccination through dendritic cells (DCs) and the potency of a subset of natural killer T lymphocytes termed cytokine-induced killer (CIK) cells led to new strategies through combining adoptive and passive immunotherapy. This review summarizes most recent clinical trials indicating that CIK cells can substantially enhance the effect of tumor vaccines and discusses the potential therapeutic benefit in the long-term control of tumor progression.
免疫系统可以通过主动（刺激患者对癌症的固有免疫反应）和被动（转移主动体液或细胞免疫）免疫疗法来对抗癌症。虽然每种策略都提供了原理验证，但由于淋巴细胞功能障碍，临床获益有限。通过树突状细胞 (DC) 接种疫苗机制和称为细胞因子诱导的杀伤 (CIK) 细胞的自然杀伤 T 淋巴细胞亚群的效力的不断增加的知识，通过结合过继免疫和被动免疫疗法产生了新的策略。这篇综述总结了最近的临床试验，表明 CIK 细胞可以显著增强肿瘤疫苗的效果，并讨论了在长期控制肿瘤进展方面的潜在治疗益处。
